OSE Immunotherapeutics to host a KOL webcast dedicated to lusvertikimab on September 2, 2026
Filed with Euronext · · 2 pages · English
OSE Immunotherapeutics SA on 6ix
Earlier from OSE Immunotherapeutics
- Informations relatives au nombre total de droits de vote et d’actions composant le capital
- OSE Immunotherapeutics Reports Results of its 2026 Annual General Meeting
- Annual General Meeting on June 24, 2026 Procedures for obtaining preparatory documents for the General Meeting
- OSE Immunotherapeutics Reports Full Year 2025 Audited Consolidated Financial Results and Announces the Filing of its 2025 Universal Registration Document
- OSE Immunotherapeutics to Implement a Flexible Bridge Equity Financing
Later from OSE Immunotherapeutics
- OSE Immunotherapeutics se félicite de l’inclusion du premier patient traité par Veloxis dans l’étude de phase 2 RENGEVITY-201 évaluant le pegrizeprument (VEL-101) dans la prévention du rejet d’organe chez les patients transplantés rénaux
- OSE Immunotherapeutics Welcomes First Patient Dosed by Veloxis in the Phase 2 RENGEVITY-201 Trial Evaluating Pegrizeprument (VEL-101) for the Prevention of Organ Rejection in Kidney Transplant Recipients
- OSE Immunotherapeutics annonce la présentation des principaux résultats de l'étude de Phase 2 Combi-TED de Tedopi® dans le cancer du poumon non à petites cellules au Congrès 2026 de l’ESMO
- OSE Immunotherapeutics Announces Presentation of Combi-TED Phase 2 Topline Results of Tedopi® in Non-Small Cell Lung Cancer at the ESMO 2026 Meeting
- OSE Immunotherapeutics Reports its Cash Position as of June 30, 2026, and Provides Business Update
Follow OSE Immunotherapeutics into a list and get an email when it puts out news.
Follow OSE Immunotherapeutics